EACS2023: 920 Lipid profile in people living with HIV after one year of antiretroviral therapy A. Lembas , A. Załęski , T. Mikuła , A. Wiercińska-Drapało Medical University of Warsaw, Department of Infectious and Tropical Diseases and Hepatology, Warsaw, Poland, Hospital for Infectious Diseases, Warsaw, Poland General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The aim of the study was the analysis of lipid profile among PLWH at the point of HIV diagnosis and the observation of changes in lipid parameters during 1 year of ART. Method: Adult newly diagnosed PLWH who started ART, continued uninterruptedly during 1-year observation and achieved complete viral suppression were analyzed. Nobody was receiving lipid-lowering therapy. CD4 cell count, CD4:CD8 ratio, HIV-1 viral load and lipid profile were examined twice – at the point of HIV diagnosis and after 12 months of ART. Results: The study included n=70 PLWH. Significant increase in total, HDL and LDL cholesterol and decrease in triglyceride concentration after 1 year of ART was observed (Table 1). Table 1. The comparison of baseline and 1 year post-treatment introduction lipid profile in PLWH. Variable Baseline After 1 year of ART p Total choloesterol (mmol/l) mean (SD*) 4.15 (1.16) 4.81 (1.08) 0.001 HDL cholesterol (mmol/l) mean (SD*) 0.84 (0.36) 1.22 (0.43) <0.001 LDL cholesterol (mmol/l) mean (SD*) 2.46 (0.43) 2.79 (0.86) 0.013 Non-HDL cholesterol (mmol/l) mean (SD*) 3.31 (1.02) 3.60 (1.05) 0.060 Trigyceride (mmol/l) mean (SD*) 1.98 (0.94) 1.82 (1.13) 0.049 *standard deviation Baseline CD4 cell count <200/μl was associated with higher baseline LDL cholesterol (p=0.036) and female gender with worse lipid parameters (Table 2). Table 2. Lipid profile differences among men and women before ART introduction. Variable Women (n=12) Men (n=58) p Total cholesterol (mmol/l) mean (SD*) 5.00 (1.22) 3.97 (1.08) 0.005 HDL cholesterol (mmol/l) mean (SD*) 1.00 (0.38) 0.81 (0.35) 0.061 LDL cholesterol (mmol/l) mean (SD*) 3.07 (1.05) 2.34 (0.85) 0.011 Non-HDL cholesterol (mmol/l) mean (SD*) 4.00 (1.08) 3.16 (0.95) 0.008 Trigyceride (mmol/l) mean (SD*) 2.36 (1.12) 1.90 (0.89) 0.086 *standard deviation PLWH with baseline CD4 cell count <200/μl had significantly higher total cholesterol (p=0.033), LDL cholesterol (p=0.009), non-HDL cholesterol (p=0.009) and triglycerides (p=0.003) after 1 year of ART than PLWH with CD4 ≥200/μl. No significant differences in lipid profile after 1 year were observed according to gender and ART scheme, except for greater increase in LDL cholesterol in people receiving elvitegravir boosted with cobicystat than bictegravir (Figure 1). Figure 1. Differences in baseline LDL cholesterol among PLWH receiving BIC- and EVG/c-based therapies. Conclusions: Healthcare providers should pay attention to lipid profile in ART-naïve patients, especially with baseline CD4 cell count <200/µl. Particular care is suggested in women. Lipid parameters should be precisely and regularly assessed in all PLWH undergoing ART, especially in patients receiving older generation antiretroviral agents. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1,2 1,2 1,2 1,2 1 2 173
RkJQdWJsaXNoZXIy Mzc2ODc=